1Lubbe AS, Bergemann C, Riess H, et al. Clinical experiences with magnetic drug targeting:a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Research, 1996,56 (20):4686-4693.
2Alexion C, Amold W, Klein RJ, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Research, 2000,60 (23): 6641-6648.
3Soma CE, Dubernet C, Baratt G, et al. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Research. 1999,16(11) :1710-1716.
4Yoo HS, Park TG. In vitro and in vivo antitum or activities of nanoparticles based on doxorubicin-PLGA conjugates. Polym Prer. 2000,41 (1):992-993.
5Guzman L, Labhasetwar V, Song C, et al. Loncal intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation, 1996,94 (4): 1441 -1448.
6Labhasetwar V, Song C, Humphrey W, et al. Nanoparticles for site specific delivery of U-86983 in Restenosis in pig coronary arteries. Proc Int Symp Control Release Bioact Master, 1995,22 (9): 182 -183.
